NAD+


Overview

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for energy metabolism, DNA repair and the activity of sirtuins — the longevity proteins. Its levels decline roughly 50% between youth and middle age, and restoring them is one of the central bets of modern longevity science.

The market offers NAD+ itself (IV drips, injections) and oral precursors (NMN, NR) that the body converts into NAD+.

How It Works

NAD+ shuttles electrons in mitochondrial energy production — without it, cells cannot make ATP. It is also consumed by enzymes like sirtuins and PARPs that regulate aging, DNA repair and inflammation. Declining NAD+ means both less energy and less repair capacity.

The delivery problem

Oral NAD+ is largely degraded in digestion, which is why clinics use IV infusions and why the precursor strategy (NMN, NR) became popular — these smaller molecules survive absorption and are converted to NAD+ inside cells. Human trials confirm precursors reliably raise blood NAD+ levels.

Key Benefits

Cellular energy — restoring NAD+ improves mitochondrial function in animal models of aging.

DNA repair capacity — PARP enzymes depend on NAD+; deficiency impairs repair.

Sirtuin activation — the longevity pathway that made NAD+ famous.

Subjective energy and clarity — the most reported effects from IV clinics, though placebo-controlled data is thin.

Side Effects & Considerations

IV NAD+ infusions commonly cause flushing, chest pressure, nausea and cramping during administration — rate-dependent and unpleasant but not dangerous. Oral precursors are well tolerated at studied doses.

The honest state of the science

Raising NAD+ in humans is proven; proving that doing so extends healthspan or lifespan is not. The animal data is spectacular, the human outcome data is early. IV NAD+ is expensive, uncomfortable and lacks trial support for most clinic claims; oral precursors are cheaper, easier and better studied for raising levels. A reasonable longevity bet — but a bet, not a fact.

Dosage protocols

Protocol Dosage Frequency Duration Notes
Oral precursors (evidence-based) NR 300-1000 mg or NMN 250-500 mg Daily Ongoing The route with human trial data for raising NAD+ levels.
IV infusion (clinic) 250-1000 mg Per clinic protocol Sessions of 2-4 hours Slow infusion rate is essential to tolerate side effects. Expensive; evidence for outcomes is weak.

Warnings

IV infusions cause rate-dependent flushing and nausea. Human longevity benefits remain unproven. Oral precursors are the better-studied route.